8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): A case report and review of the literature

Acta Haematologica

Volumn 133, Issue 1, 2015, Pages 101-105

  Kim, Woo Seong ^a   Park, Sang Gon ^a   Park, Geon ^a   Jang, Sook Jin ^a   Moon, Dae Soo ^a   Kang, Seong Ho ^a  

^a Chosun University College of Medicine   (South Korea)

Author keywords

8p11 myeloproliferative syndrome; T lymphoblastic lymphoma; t(1; 8)(q25; p11.2)

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 2; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

8P11 MYELOPROLIFERATIVE SYNDROME; ADULT; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME 8P; CHROMOSOME TRANSLOCATION; EOSINOPHIL COUNT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GINGIVA BLEEDING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEG EDEMA; LEUKOCYTE COUNT; LYMPHADENOPATHY; LYMPHOBLASTOMA; MALE; MIDDLE AGED; MONOCYTOSIS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROMYELOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SKIN BIOPSY; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT REFUSAL; CHROMOSOME 1; CHROMOSOME 8; CHROMOSOME BANDING PATTERN; COMPUTER ASSISTED TOMOGRAPHY; GENE TRANSLOCATION; GENETICS; LYMPH NODE; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; SKIN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; SKIN; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84925547563     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000363441     Document Type: Review

References (18)

1. Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC: A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995; 9: 1628-1630.
2. Yang JJ, Park TS, Choi JR, Park SJ, Cho SY, Jun KR, Kim HR, Lee JN, Oh SH, Lee S, Kim B, Marschalek R, Meyer C: Submicroscopic deletion of FGFR1 gene is recurrently detected in myeloid and lymphoid neoplasms associated with ZMYM2-FGFR1 rearrangements: a case study. Acta Haematol 2012; 127: 119-123.
3. Swerdllow S, Campo E, Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008.
4. Li F, Zhai YP, Tang YM, Wang LP, Wan PJ: Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2012; 51: 890-897.
5. Jackson CC, Medeiros LJ, Miranda RN: 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41: 461-476.
6. Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P: The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7; 8)(q22;p11). Haematologica 2011; 96: 922-926.
7. Popovici C, Adelaide J, Ollendorff V, Chaffanet M, Guasch G, Jacrot M, Leroux D, Birnbaum D, Pebusque MJ: Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8; 13). Proc Natl Acad Sci USA 1998; 95: 5712-5717.
8. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC, Goncalves C, Hernandez JM, Jennings BA, Goldman JM, Cross NC: Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8; 13) (p11;q12) myeloproliferative syndrome. Blood 1998; 92: 1735-1742.
9. Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, Fabbro D, Roesel J, Banerji L, Griffin JD, Xiao S, Fletcher JA, Stone RM, Gilliland DG: PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 14479-14484.
10. Macdonald D, Sheerin SM, Cross NC, Spencer A, Goldman JM: An atypical myeloproliferative disorder with t(8; 13)(p11;q12): a third case. Br J Haematol 1994; 86: 879-880.
11. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Graff A, Hehlmann R, Cross NC, Reiter A: The t(8; 17) (p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 2005; 19: 1005-1009.
12. Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV: t(8; 13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol 2008; 32: 14-20.
13. Shimanuki M, Sonoki T, Hosoi H, Watanuki J, Murata S, Mushino T, Kuriyama K, Tamura S, Hatanaka K, Hanaoka N, Nakakuma H: Acute leukemia showing t(8; 22)(p11;q11), myelodysplasia, CD13/CD33/CD19 expression and immunoglobulin heavy chain gene rearrangement. Acta Haematol 2013; 129: 238-242.
14. Hu S, He Y, Zhu X, Li J, He H: Myeloproliferative disorders with t(8; 9)(p12;q33): Aacase report and review of the literature. Pediatr Hematol Oncol 2011; 28: 140-146.
15. Xu XM, Rose A, Muthuswamy S, Jeong SY, Venkatakrishnan S, Zhao Q, Meier I: Nuclear pore anchor, the arabidopsis homolog of Tpr/ Mlp1/Mlp2/megator, is involved in mRNA export and SUMO homeostasis and affects diverse aspects of plant development. Plant Cell 2007; 19: 1537-1548.
16. Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, Li XJ: Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005; 37: 198-204.
17. Soman NR, Correa P, Ruiz BA, Wogan GN: The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 1991; 88: 4892-4896.
18. Yoshida C, Takeuchi M, Sadahira Y: A novel t(1; 8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. Br J Haematol 2012; 156: 271-273.